Verastem and LabCorp partner to validate biomarker for cancer Verastem (VSTM) entered an agreement with LabCorp (LH) to validate biomarkers for its lead focal adhesion kinase inhibitor VS-6063 in the development of an applicable companion diagnostic. The biomarkers will be the subject of clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to initiate later this year.
News For VSTM;LH From The Last 14 Days
Check below for free stories on VSTM;LH the last two weeks.
UBS to host a conference Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link